Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Covadonga Figaredo"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Elena Galve, Fernando Pikabea-Diaz, Borja Lopez-de-San-Vicente-Hernandez, Covadonga Figaredo-Berjano, Jairo Legaspi-Folgueira, Maria Angeles Sala-Gonzalez, Juan Fernando Arango-Arteaga, Sara Fernandez-Ferrer, Pablo Leonardo Loaiza-Jaramillo, Pablo Casado-Cuesta, Marina Temino-Frances, Anne Bilbao-Penas, Purificacion Martinez-del-Prado
Publikováno v:
Cancer Research. 83:P1-07
Background: Recent data suggest that HER2-low breast cancer (BC) may represent a distinct entity. Approximately 55-60% of BC are considered as Her2-low, of which 80% are Luminal-like tumors. Recent studies support potential clinic-pathological and mo
Autor:
Juan Fernando Arango arteaga, Jairo Legaspi Folgueira, Maria Purificacion Martínez del Prado, Maria Angeles Sala Gonzalez, María Teresa Abad Villar, Laura Sande Sardina, Fernando Pikabea Diaz, Borja Lopez De San Vicente, Maria Teresa Perez hoyos, Covadonga Figaredo Berjano, Maitane Nuño Escolástico, Patricia Novas Vidal, Ane Zumárraga Cuesta, Elena Calvo, Maria Lopez Santillan
Publikováno v:
Cancer Research. 80:P3-14
Introduction: Oncotype DX (ODX) Recurrence Score (RS) is a gene-expression assay that provides prognostic and predictive information in hormonal-receptor positive (HR +), human epidermal growth factor receptor 2 negative (HER2-), axilary lymph node n
Autor:
Maria Teresa Perez hoyos, Maria Lopez Santillan, Juan Fernando Arango, Maitane Nuño, Borja Lopez De San Vicente, Laura Sande, Purificación Martínez, Patricia Novas, María Ángeles Sala, Elena Calvo, Ane Zumarraga, Maria Teresa Abad, Jairo Legaspi, L. Zubiri, Covadonga Figaredo, Fernando Pikabea
Publikováno v:
Journal of Clinical Oncology. 36:e13029-e13029
e13029Background: De novo metastatic breast cancer (dnMBC) represents approximately 6–10% of breast cancer. In luminal-like dnMBC recommendation for endocrine therapy (ET) as first-line treatment i...